MxA mRNA quantification and disability progression in interferon beta-treated multiple sclerosis patients

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Serana, Federico ^a   Imberti, Luisa ^a   Amato, Maria Pia ^b   Comi, Giancarlo ^c   Gasperini, Claudio ^d   Ghezzi, Angelo ^e   Martinelli, Vittorio ^c   Provinciali, Leandro ^f   Rottoli, Maria Rosa ^g   Sotgiu, Stefano ^h   Stecchi, Sergio ⁱ   Vecchio, Michele ^j   Zaffaroni, Mauro ^e   Cordioli, Cinzia ^k   Capra, Ruggero ^k  

^a CREA Diagnostics Department Spedali Civili of Brescia   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^e Gallarate Hospital   (Italy)

^f OSPEDALI RIUNITI   (Italy)

^g PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^h UNIVERSITY OF SASSARI   (Italy)

ⁱ IRCCS ISTITUTO DELLE SCIENZE NEUROLOGICHE DI BOLOGNA   (Italy)

^j S Elia Hospital   (Italy)

^k Multiple Sclerosis Center   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; INTERFERON RECEPTOR; MYXOVIRUS RESISTANCE PROTEIN A; ALPHA BETA INTERFERON RECEPTOR; BIOLOGICAL MARKER; ISOPROTEIN; MESSENGER RNA; MYXOVIRUS RESISTANCE PROTEIN; NEUTRALIZING ANTIBODY; PROTEIN SUBUNIT;

ADULT; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; ASSAY; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISABILITY; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; RADIOIMMUNOPRECIPITATION; REAL TIME POLYMERASE CHAIN REACTION; RELAPSE; TREATMENT RESPONSE; ADOLESCENT; DISEASE COURSE; GENETICS; KINETICS; METABOLISM; MIDDLE AGED; PATIENT DROPOUTS; PROTEIN SUBUNIT; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; BIOLOGICAL MARKERS; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; INTERFERON-BETA; KINETICS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MYXOVIRUS RESISTANCE PROTEINS; PATIENT DROPOUTS; PROTEIN ISOFORMS; PROTEIN SUBUNITS; RECEPTOR, INTERFERON ALPHA-BETA; RNA, MESSENGER; YOUNG ADULT;

EID: 84899660160     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094794     Document Type: Article

References (36)

1. Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E (2004) Defining interferon b response status in multiple sclerosis patients. Ann Neurol 56: 548-555. (Pubitemid 39319345)
2. Menzin J, Caon C, Nichols C, White LA, Friedman M, et al. (2013) Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J Manag Care Pharm 19: S24-40.
3. Giacomini PS, Arnold DL, Bar-Or A, Antel JP (2009) Defining multiple sclerosis treatment response with magnetic resonance imaging: How much activity is too much? Arch Neurol 66: 19-20.
4. Ŕo J, Comabella M, Montalban X (2009) Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol 5: 553-560.
5. Killestein J, Polman CH (2011) Determinants of interferon b efficacy in patients with multiple sclerosis. Nat Rev Neurol 7: 221-228.
6. Sormani MP, Bonzano L, Roccatagliata L, Cutter GR, Mancardi GL, et al. (2009) Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta-analytic approach. Ann Neurol 65: 268-275.
7. Goodin DS, Frohman EM, Garmany GP, Halper J, Likosky WH, et al. (2002) Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58: 169-178. (Pubitemid 34086933)
8. Sørensen PS, Deisenhammer F, Duda P, Hohlfeld R, Myhr KM, et al. (2005) Guidelines on use of anti-IFN-b antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-b antibodies in multiple sclerosis. Eur J Neurol 12: 817-827. (Pubitemid 41597593)
9. Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung HP, et al. (2010) Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 9: 740-750.
10. Bellomi F, Bramanti P, Trojano M, Scagnolari C, Muto A, et al. (2009) Neutralizing and binding antibodies to interferon beta in patients with multiple sclerosis: a comparison of assay results from three italian centres. J Immunoassay Immunochem 30: 40-50.
11. Hartung HP, Kieseier B, Goodin DS, Arnason BG, Comi G, et al. (2012) Variability in detection and quantification of interferon b-1b-induced neutralizing antibodies. J Neuroinflammation 9: 129.
12. Chiu AW, Ehrmantraut M, Richert ND, Ikonomidou VN, Pellegrini S, et al. (2007) A case study on the effect of neutralizing antibodies to interferon beta 1b in multiple sclerosis patients followed for 3 years with monthly imaging. Clin Exp Immunol 150: 61-67. (Pubitemid 47383299)
13. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, et al. (2001) Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50: 121-127.
14. Capra R, Sottini A, Cordioli C, Serana F, Chiarini M, et al. (2007) IFN beta bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays. J Neuroimmunol 189: 102-110. (Pubitemid 47385828)
15. Antonelli G, Bagnato F, Pozzilli C, Simeoni E, Bastianelli S, et al. (1998) Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta1a. J Interferon Cytokine Res 18: 345-350. (Pubitemid 28226180)
16. Vitale G, de Herder WW, van Koetsveld PM, Waaijers M, Schoordijk W, et al. (2006) IFN-b Is a Highly Potent Inhibitor of Gastroenteropancreatic Neuroendocrine Tumor Cell Growth In vitro. Cancer Res 66: 554-562. (Pubitemid 43166064)
17. Serana F, Sottini A, Ghidini C, Zanotti C, Capra R, et al. (2008) Modulation of IFNAR1 mRNA expression in multiple sclerosis patients. J Neuroimmunol 197: 54-62.
18. Zanotti C, Ghidini C, Lamorgese C, Caimi L, Capra R, et al. (2010) Transfer of myxovirus-protein-A mRNA assay for interferon-beta bioactivity measurement in multiple sclerosis patients to routine laboratory practice. A 4-year experience. Clin Chem Lab Med 48: 1235-1238.
19. Lampasona V, Rio J, Franciotta D, Furlan R, Avolio C, et al. (2003) Serial immunoprecipitation assays for interferon-(IFN)-beta antibodies in multiple sclerosis patients. Eur Cytokine Netw 14: 154-157. (Pubitemid 37249234)
20. Oliver B, Mayorga C, Fernández V, Leyva L, León A, et al. (2007) Interferon receptor expression in multiple sclerosis patients. J Neuroimmunol 183: 225-231. (Pubitemid 46204911)
21. Gilli F, Marnetto F, Caldano M, Valentino P, Granieri L, et al. (2007) Antiinterferon-b neutralising activity is not entirely mediated by antibodies. J Neuroimmunol 192: 198-205. (Pubitemid 350213126)
22. Gilli F, Valentino P, Caldano M, Granieri L, Capobianco M, et al. (2008) Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis. Neurology 71: 1940-1947.
23. Noseworthy JH, Vandervoort MK, Wong CJ, Ebers GC (1990) Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group. Neurology 40: 971-975. (Pubitemid 20201827)
24. Rudick RA, Lee J, Cutter GR, Miller DM, Bourdette D, et al (2010) Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: Eight-year follow-up. Arch Neurol 67: 1329-1335.
25. Van der Voort LF, Vennegoor A, Visser A, Knol DL, Uitdehaag BMJ, et al. (2010) Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS. Neurology 75: 1228-1233.
26. Malucchi S, Gilli F, Caldano M, Sala A, Capobianco M, et al. (2010) One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients. J Neurol 258: 895-903.
27. Hesse D, Sellebjerg F, Sorensen PS (2009) Absence of MxA induction by interferon b in patients with MS reflects complete loss of bioactivity. Neurology 73: 372-377.
28. Pachner AR, Narayan K, Price N, Hurd M, Dail D (2003) MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity. Mol Diagn 7: 17-25. (Pubitemid 37339029)
29. Hardy MP, Owczarek CM, Trajanovska S, Liu X, Kola I, et al. (2001) The soluble murine type I interferon receptor Ifnar-2 is present in serum, is independently regulated, and has both agonistic and antagonistic properties. Blood 97: 473-482. (Pubitemid 32060333)
30. Gilli F (2010) Role of differential expression of interferon receptor isoforms on the response of multiple sclerosis patients to therapy with interferon beta. J Interferon Cytokine Res 30: 733-741.
31. Feng X, Han D, Kilaru BK, Franek BS, Niewold TB, et al. (2012) Inhibition of interferon-beta responses in multiple sclerosis immune cells associated with highdose statins. Arch Neurol 69: 1303-1309.
32. Hemmer B, Berthele A (2009) Should we measure the bioavailability of interferon beta in vivo in patients with multiple sclerosis? Nat Clin Pract Neurol 5: 126-127.
33. Cunningham S, Graham C, Hutchinson M, Droogan A, O'Rourke K, et al. (2005) Pharmacogenomics of responsiveness to interferon IFN-b treatment in multiple sclerosis: A genetic screen of 100 type I interferon-inducible genes. Clin Pharmacol Ther 78: 635-646.
34. Malucchi S, Gilli F, Caldano M, Marnetto F, Valentino P, et al. (2008) Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology 70: 1119-1127. (Pubitemid 351464769)
35. Ŕo J, Nos C, Tintoré M, Téllez N, Galán I, et al. (2006) Defining the response to interferon-b in relapsing-remitting multiple sclerosis patients. Ann Neurol 59: 344-352. (Pubitemid 43202488)
36. Chiu AW, Richert N, Ehrmantraut M, Ohayon J, Gupta S, et al. (2009) Heterogeneity in response to interferon beta in patients with multiple sclerosis: a 3-year monthly imaging study. Arch Neurol 66: 39-43.